Bayer AG (BAYN.XE) said Wednesday its cooperation partner, Johnson & Johnson’s (JNJ) Janssen Research & Development LLC, has applied to the U.S. Food and Drug Administration for approval for its oral anticoagulant Xarelto to reduce the risk of stent thrombosis in patients with acute coronary syndrome, or ACS. -Stent thrombosis is a rare condition that occurs when a blood clot forms on a stent, which is a tube inserted into a patient’s coronary artery to keep the passageway open. -An application for marketing authorization to reduce the risk of secondary cardiovascular events in patients with ACS was filed with the FDA in December and is currently under review.
